Thanks for the summary.

I did appreciate the general overview of the updated trail design in yesterday's presentation, and reference to the alternative, larger trial proposed by potential partners.  However, it seems to me that with them choosing the "Targeted" development plan (with the trial design you summarized), that Covid should not have a major detrimental affect on recruitment or initiation of the trial.

Don has indicated in the past that cancer trials are not affected by the Covid environment, which makes sense because these are sick patients that can not and will not put off doctor visits at any time and for any reason (reference Zenith).  Being that he stressed that the preferred trial design will be recuruiting from a sicker population, these patients, too, should not be putting of in-person doctor visits in the current environment.  I call bulls**t on this excuse for delays in trial initiation. 

Overall, I am confident that they have been in discussuions with potential partners, especially given his reference of the preferred chemistry upgrades.  Hopefully they are getting closer to a final agreement and will be able to announce something in the near future.  I'm sure part of the delay has been BP evaluating the probability of succcess of whatever trial they will be funding (perhaps the larger trial is deemed safer - even though more expensive).  I like his point of the chemistry upgrades being done in conjunction with the smaller trial, as opposed to being completed prior to initiation.  I think they are close here and look forward to hearing more on initiation of BOM2 over the next couple of months.  

I also share his enthusiasm of the Covid trial - its a shame they could not have inittaed this this past fall.